{"organizations": [], "uuid": "ef966a6fcda813c3bd2c35c2b70535b322b83845", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regeneron-says-phase-3-trial-of-du/brief-regeneron-says-phase-3-trial-of-dupixent-met-primary-endpoints-idUSASC0A2JF", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary Endpoints", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.478, "site_type": "news", "published": "2018-05-16T13:05:00.000+03:00", "replies_count": 0, "uuid": "ef966a6fcda813c3bd2c35c2b70535b322b83845"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regeneron-says-phase-3-trial-of-du/brief-regeneron-says-phase-3-trial-of-dupixent-met-primary-endpoints-idUSASC0A2JF", "ord_in_thread": 0, "title": "BRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary Endpoints", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-regeneron", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Regeneron Pharmaceuticals Inc:\n* POSITIVE PHASE 3 TRIAL OF DUPIXENTÂ® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS\n* U.S. REGULATORY SUBMISSION FOR PATIENTS AGES 12-17 PLANNED FOR Q3 2018\n* CO, SANOFI SAID PIVOTAL PHASE 3 TRIAL EVALUATING DUPIXENT MET PRIMARY AND KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T13:05:00.000+03:00", "crawled": "2018-05-17T14:41:07.000+03:00", "highlightTitle": ""}